PDSB - Intellia in focus after landmark trial data Unity Biotech wins double upgrade: in today's analyst action

Mario13/E+ via Getty Images Intellia has a “more de-risked platform” now: Jefferies Intellia Therapeutics (NTLA) and Regeneron (REGN) have climbed sharply in the pre-market after the duo marked a milestone in CRISPR gene-editing with interim results for NTLA-2001 in transthyretin amyloidosis ((ATTR)). With first-ever in-vivo clinical data supporting the safety and efficacy of CRISPR genome editing, Intellia now has “a more de-risked platform with this capability,” Jefferies analysts led by Maury Raycroft wrote. The “better than expected” results have met the high bar the company has set for the treatment ahead of the data readout, Raycroft and the team noted with a buy rating on the stock. Last week, RBC Capital Markets predicted a sharp upside for Intellia shares subject to favorable results for NTLA-2001. In the pre-market today, other stocks in the gene-editing space have moved higher in solidarity with Intellia. Global Blood Therapeutics cut to neutral at JPM on mixed views

For further details see:

Intellia in focus after landmark trial data, Unity Biotech wins double upgrade: in today's analyst action